{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:40:25Z","timestamp":1783647625190,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002960","name":"V\u00e4sterbotten L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["RV-995135"],"award-info":[{"award-number":["RV-995135"]}],"id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","award":["NNF23OC0082689"],"award-info":[{"award-number":["NNF23OC0082689"]}],"id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hereditary transthyretin (ATTRv) amyloidosis is a rare but life-threatening multisystemic disease. Multiple disease-modifying treatments are now available and standardised instruments for early detection and disease monitoring are essential. Still, validated and easy-to-use tools for clinical follow-up are scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The Kumamoto scale was first described in 1997 as a method for systematically evaluating patients with ATTRv amyloidosis and has been used in clinical trials since. A panel of amyloidosis experts from Sweden, Denmark, and Norway discussed the strengths and limitations of the Kumamoto scale at the Nordic Amyloidosis Day at Arlanda in 2023, and it was decided to revise and improve the scale that has been used in routine clinical monitoring of patients in Sweden since 2020. Our aim is to introduce the revised version of the Kumamoto scale as a useful clinical monitoring tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Minor adjustments were applied to make the scale more sensitive and precise. Bedside instruments for sensory examination were defined as well as the sensory and motor levels. Constipation was added as a sign of autonomic dysfunction. The subtotal and total scores remain unchanged.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We believe that the revised Kumamoto scale is a reliable and easy-to-use clinical tool for monitoring ATTRv amyloidosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03915-w","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:14:26Z","timestamp":1753452866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Introducing a revised version of the Kumamoto scale as an easy-to-use clinical tool for monitoring multisystemic changes in hereditary transthyretin amyloidosis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-1277","authenticated-orcid":false,"given":"Jonas","family":"Wixner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Pilebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tale N.","family":"Wien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Eldhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"M\u00f6lgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Hedstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid J.","family":"Terkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"2","key":"3915_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14797\/mdcvj.1066","volume":"18","author":"CA Obi","year":"2022","unstructured":"Obi CA, Mostertz WC, Griffin JM, et al. ATTR epidemiology, genetics, and prognostic factors. Methodist Debakey Cardiovasc J. 2022;18(2):17\u201326.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"4","key":"3915_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281(4):337\u201347.","journal-title":"J Intern Med"},{"issue":"9","key":"3915_CR3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120\u20137.","journal-title":"Eur Heart J"},{"key":"3915_CR4","first-page":"1","volume":"590","author":"R Andersson","year":"1976","unstructured":"Andersson R. Familial amyloidosis with polyneuropathy: a clinical study based on patients living in northern Sweden. Acta Med Scand Suppl. 1976;590:1\u201364.","journal-title":"Acta Med Scand Suppl"},{"key":"3915_CR5","unstructured":"Coutinho P, Martins da Silva A, Lopes Lima J, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980. pp. 88\u201398."},{"issue":"21","key":"3915_CR6","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","volume":"91","author":"T Coelho","year":"2018","unstructured":"Coelho T, In\u00eas M, Concei\u00e7\u00e3o I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999\u20132009.","journal-title":"Neurology"},{"issue":"5","key":"3915_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/brainsci11050545","volume":"11","author":"M Russo","year":"2021","unstructured":"Russo M, Gentile L, Di Stefano V, et al. Use of drugs for ATTRv amyloidosis in the real world: how therapy is changing survival in a non-endemic area. Brain Sci. 2021;11(5):545.","journal-title":"Brain Sci"},{"issue":"5","key":"3915_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0025-6196(12)60388-7","volume":"67","author":"MA Gertz","year":"1992","unstructured":"Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc. 1992;67(5):428\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"3915_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123\u201331.","journal-title":"Amyloid"},{"key":"3915_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000574","author":"B-G Ericzon","year":"2015","unstructured":"Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: After 20 years still the best therapeutic alternative? Transplantation. 2015. https:\/\/doi.org\/10.1097\/TP.0000000000000574.","journal-title":"Transplantation"},{"issue":"8","key":"3915_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology"},{"issue":"11","key":"3915_CR12","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802\u201314.","journal-title":"J Neurol"},{"issue":"24","key":"3915_CR13","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658\u201367.","journal-title":"JAMA"},{"issue":"11","key":"3915_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"3915_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"3915_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"3915_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"key":"3915_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023. https:\/\/doi.org\/10.1080\/13506129.2022.2091985.","journal-title":"Amyloid"},{"issue":"15","key":"3915_CR19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358.","journal-title":"JAMA"},{"key":"3915_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","author":"M Fontana","year":"2024","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"},{"issue":"15","key":"3915_CR21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141(15):1214\u201324.","journal-title":"Circulation"},{"key":"3915_CR22","first-page":"21202","volume":"119","author":"J Wixner","year":"2022","unstructured":"Wixner J, Anan I, Pilebro B, et al. Hereditary transthyretin amyloidosis\u2014from symptomatic to curative treatment? Lakartidningen. 2022;119:21202.","journal-title":"Lakartidningen"},{"issue":"4","key":"3915_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431\u201343.","journal-title":"Circulation"},{"issue":"30","key":"3915_CR24","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"key":"3915_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116424","volume":"405","author":"PJB Dyck","year":"2019","unstructured":"Dyck PJB, Gonz\u00e1lez-Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. J Neurol Sci. 2019;405: 116424.","journal-title":"J Neurol Sci"},{"issue":"1","key":"3915_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3915_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","volume":"26","author":"I Concei\u00e7\u00e3o","year":"2019","unstructured":"Concei\u00e7\u00e3o I, Coelho T, Rapezzi C, et al. Assessment of patients with hereditary transthyretin amyloidosis: understanding the impact of management and disease progression. Amyloid. 2019;26(3):103\u201311.","journal-title":"Amyloid"},{"issue":"1","key":"3915_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","volume":"16","author":"D Adams","year":"2021","unstructured":"Adams D, Algalarrondo V, Polydefkis M, et al. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021;16(1):411.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3915_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/cjn.2021.34","volume":"49","author":"M Alcantara","year":"2022","unstructured":"Alcantara M, Mezei MM, Baker SK, et al. Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management. Can J Neurol Sci. 2022;49(1):7\u201318.","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"3915_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143\u201355.","journal-title":"Amyloid"},{"issue":"3","key":"3915_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1055\/s-0043-1764412","volume":"81","author":"MV Pinto","year":"2023","unstructured":"Pinto MV, Fran\u00e7a MC, Gon\u00e7alves MVM, et al. Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition. Arq Neuropsiquiatr. 2023;81(3):308\u201321.","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"3915_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/13506129708995279","volume":"4","author":"K Tashima","year":"1997","unstructured":"Tashima K, Ando Y, Ando E, et al. Heterogeneity of clinical symptoms in patients with familial amyloidotic polyneuropathy (FAP TTR Met30). Amyloid. 1997;4(2):108\u201311.","journal-title":"Amyloid"},{"issue":"sup1","key":"3915_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13506129.2019.1593133","volume":"26","author":"J Wixner","year":"2019","unstructured":"Wixner J, Westermark P, Ihse E, et al. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition. Amyloid. 2019;26(sup1):39\u201340.","journal-title":"Amyloid"},{"issue":"1","key":"3915_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-510X(99)00231-2","volume":"171","author":"K Tashima","year":"1999","unstructured":"Tashima K, Ando Y, Terazaki H, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci. 1999;171(1):19\u201323.","journal-title":"J Neurol Sci"},{"key":"3915_CR35","unstructured":"NT-r\u00e5dets expertgrupp f\u00f6r transtyretinamyloidos. Tegsedi (inotersen) och Onpattro (patisiran) vid \u00e4rftlig transtyretinamyloidos (ATTRv-amyloidos, Skelleftesjukan). NT\u00ad-r\u00e5dets yttrande till regionerna 2021-09-03. [cited 2021 Sep 6]. Available from: https:\/\/janusinfo.se\/nationelltinforandeavlakemedel\/produktinfo\/onpattropatisiran."},{"key":"3915_CR36","unstructured":"Opstart og seponering for tafamidis til arvelig transthyretinmedieret amyloidose med polyneuropati stadie 1. Medicinr\u00e5det; Available from: https:\/\/medicinraadet-dk.b-cdn.net\/media\/t3hd4wgn\/medicinr%C3%A5dets-pr%C3%A6cisering-vedr-opstart-og-seponering-for-tafamidis_adlegacy.pdf."},{"issue":"10","key":"3915_CR37","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/ejp.1456","volume":"23","author":"GC Zhu","year":"2019","unstructured":"Zhu GC, B\u00f6ttger K, Slater H, et al. Concurrent validity of a low-cost and time-efficient clinical sensory test battery to evaluate somatosensory dysfunction. Eur J Pain. 2019;23(10):1826\u201338.","journal-title":"Eur J Pain"},{"issue":"3","key":"3915_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000820","volume":"5","author":"M Reimer","year":"2020","unstructured":"Reimer M, Forstenpointner J, Hartmann A, et al. Sensory bedside testing: a simple stratification approach for sensory phenotyping. Pain Rep. 2020;5(3): e820.","journal-title":"Pain Rep"},{"issue":"10","key":"3915_CR39","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/pm\/pnaa192","volume":"21","author":"AE Koulouris","year":"2020","unstructured":"Koulouris AE, Edwards RR, Dorado K, et al. Reliability and validity of the Boston bedside quantitative sensory testing battery for neuropathic pain. Pain Med. 2020;21(10):2336\u201347.","journal-title":"Pain Med"},{"issue":"7\u20138","key":"3915_CR40","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jpain.2019.11.013","volume":"21","author":"AD Wasan","year":"2020","unstructured":"Wasan AD, Alter BJ, Edwards RR, et al. Test-retest and inter-examiner reliability of a novel bedside quantitative sensory testing battery in postherpetic neuralgia patients. J Pain. 2020;21(7\u20138):858\u201368.","journal-title":"J Pain"},{"issue":"2","key":"3915_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/SPC.0000000000000556","volume":"15","author":"M Reimer","year":"2021","unstructured":"Reimer M, Sachau J, Forstenpointner J, et al. Bedside testing for precision pain medicine. Curr Opin Support Palliat Care. 2021;15(2):116\u201324.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"5","key":"3915_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1464-5491.2002.00706.x","volume":"19","author":"AN Paisley","year":"2002","unstructured":"Paisley AN, Abbott CA, van Schie CHM, et al. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med. 2002;19(5):400\u20135.","journal-title":"Diabet Med"},{"issue":"2","key":"3915_CR43","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10072-021-05434-5","volume":"43","author":"L Leonardi","year":"2022","unstructured":"Leonardi L, Galosi E, Vanoli F, et al. Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation. Neurol Sci. 2022;43(2):1359\u201364.","journal-title":"Neurol Sci"},{"issue":"3","key":"3915_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1529-8027.2008.00180.x","volume":"13","author":"JR Singleton","year":"2008","unstructured":"Singleton JR, Bixby B, Russell JW, et al. The Utah early neuropathy scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008;13(3):218\u201327.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"3915_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/archneur.1981.00510010072013","volume":"38","author":"SG Waxman","year":"1981","unstructured":"Waxman SG, Sabin TD. Diabetic truncal polyneuropathy. Arch Neurol. 1981;38(1):46\u20137.","journal-title":"Arch Neurol"},{"issue":"1","key":"3915_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17474124.2018.1397511","volume":"12","author":"J Wixner","year":"2018","unstructured":"Wixner J, Suhr OB, Anan I. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years. Expert Rev Gastroenterol Hepatol. 2018;12(1):73\u201381.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"8","key":"3915_CR47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00415-016-8375-x","volume":"264","author":"CH Gibbons","year":"2017","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567\u201382.","journal-title":"J Neurol"},{"issue":"11","key":"3915_CR48","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Mech\u00e9 FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve. 1991;14(11):1103\u20139.","journal-title":"Muscle Nerve"},{"key":"3915_CR49","unstructured":"Eva Joelsson-Alm, Thulin H. Schema f\u00f6r kontroll av bl\u00e5st\u00f6mning [Internet]. V\u00e5rdhandboken. 2024. Available from: https:\/\/www.vardhandboken.se\/vard-och-behandling\/basal-och-preventiv-omvardnad\/blasovervakning-vid-sjukhusvard\/schema-for-kontroll-av-blastomning\/."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03915-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03915-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03915-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:41:23Z","timestamp":1757288483000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03915-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3915"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03915-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alnylam Pharmaceuticals sponsored the Nordic Amyloidosis Day but did not participate in the planning of the study or in the writing of the manuscript. The authors have no other conflicts of interest to declare for this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since no patient data was included, no consent for publication was needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No new data was collected and, thus, no ethical approval or consent to participate was necessary for the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"377"}}